98%
921
2 minutes
20
Background: Hyaluronic acids (HAs) continue to be the fillers of choice worldwide and their popularity is growing. Adverse events (AEs) are able to be resolved through the use of hyaluronidase (HYAL). However, routine HYAL use has been at issue due to perceived safety issues.
Objectives: There are currently no guidelines on the use of HYAL in aesthetic practice, leading to variability in storage, preparation, skin testing, and beliefs concerning AEs. This manuscript interrogated the use of this agent in daily practice.
Methods: A 39-question survey concerning HYAL practice was completed by 264 healthcare practitioners: 244 from interrogated databases and 20 from the consensus panel. Answers from those in the database were compared to those of the consensus panel.
Results: Compared to the database group, the consensus group was more confident in the preparation of HYAL, kept reconstituted HYAL for longer, and was less likely to skin test for HYAL sensitivity and more likely to treat with HYAL in an emergency, even in those with a wasp or bee sting anaphylactic history. Ninety-two percent of all respondents had never observed an acute reaction to HYAL. Just over 1% of respondents had ever observed anaphylaxis. Five percent of practitioners reported longer-term adverse effects, including 3 respondents who reported loss of deep tissues. Consent before injecting HA for the possible requirement of HYAL was always obtained by 74% of practitioners.
Conclusions: Hyaluronidase would appear to be an essential agent for anyone injecting hyaluronic acid filler. However, there is an absence of evidence-based recommendations with respect to the concentration, dosing, and treatment intervals of HYAL, and these should ideally be available.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11093658 | PMC |
http://dx.doi.org/10.1093/asj/sjae009 | DOI Listing |
Toxins (Basel)
August 2025
Laboratório Bioquímica e Biofísica, Instituto Butantan, São Paulo 05503-900, Brazil.
, commonly known as the death adder, is a venomous Australian snake and a member of the Elapidae family. Due to its robust body and triangular head, it was historically misclassified as a viper. Its venom is known for neurotoxic, hemorrhagic, and hemolytic effects but displays low anticoagulant activity.
View Article and Find Full Text PDFInt J Pharm
October 2025
Department of Pharmacognosy, Faculty of Pharmacy, Academy of Medicine, Lithuanian University of Health Sciences, Sukilėlių Av. 13, 50162 Kaunas, Lithuania. Electronic address:
This study aimed to develop and evaluate cyano-phycocyanin (C-PC)-loaded enriched transfersomes for topical application, improved skin delivery, and antioxidant protection. The main objective was to overcome the limitations associated with C-PC's instability and poor skin permeability due to its high molecular weight and hydrophilicity. Six formulations were prepared using an organic solvent-free two-step method: glycerol-enriched transfersomes (Gly-transfersomes),glycerol and cholesterol-enriched transfersomes (Gly-chol-transfersomes),hyaluronate-enriched transfersomes (Hyal-transfersomes),hyaluronate and cholesterol-enriched transfersomes (Hyal-chol-transfersomes),glycerol and hyaluronate-enriched transfersomes (Hyal-gly-transfersomes), anda combination of all three (Hyal-gly-chol-transfersomes).
View Article and Find Full Text PDFFront Med (Lausanne)
July 2025
Skin Research Center, Shohada-e Tajrish Hospital, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Introduction: Hyaluronic acid (HA) fillers are generally safe; however, the most significant complication is vascular occlusion. Several therapeutic protocols have been proposed for managing ischemia. De Lorenzi introduced the HDPH protocol, which uses a minimum of 500 IU of hyaluronidase (HYAL) per ischemic area.
View Article and Find Full Text PDFAesthetic Plast Surg
August 2025
Department of Facial Plastic and Cranio-Maxillo-Facial Surgery, Fakih Hospital, Khaizaran Main Street, Khaizaran, 00000, Lebanon.
Introduction: Prompt management of vascular occlusion from hyaluronic acid (HA) fillers is crucial to prevent permanent tissue damage. This study reviews key factors influencing clinical outcomes-excluding ocular cases-and evaluates current protocols and modern treatment strategies METHODS: A systematic literature review was conducted to develop an action guide for managing vascular occlusion, focusing on both technical and pharmacological aspects. The search prioritized publications with significant clinical impact and expert guidelines, excluding older studies to ensure alignment with modern angiosome concepts and recent advancements in interventional radiology.
View Article and Find Full Text PDFAesthet Surg J
June 2025
Plastic surgeon in private practice, Westmount, Quebec, Canada.
Background: The mainstay of treatment in HA filler adverse events is the use of hyaluronidase; however, the dose and dilution are not standardized.
Objectives: The objective of this study is to examine differential dilutions and concentrations of HYAL, as well as comparing the effectiveness of ovine to human HYAL.
Methods: Fillers were selected for study based on a variety of rheologic factors.